open access
Acute myeloid leukemia – treatment of relapsed and refractory form
Affiliations- Katedra i Klinika Hematologii, Uniwersytet Jagielloński Collegium Medicum, Kierownik: prof. dr hab. med. Aleksander B. Skotnicki, Kraków, Polska
open access
Abstract
Relapsed and refractory acute myeloid leukemia (AML) is defined by clinical and biologic features that predict their poor response to therapy. Despite even the most aggressive and well-developed strategies for treatment, most patients succumb to the disease. No currently available treatment has demonstrated consistent efficacy in terms of salvage therapy or long-term survival in this group of patients. This review will discuss some of the emerging strategies: targeted molecular therapies, novel cytotoxics, and immune-based therapies to treat relapsed and refractory AML patients.
Abstract
Relapsed and refractory acute myeloid leukemia (AML) is defined by clinical and biologic features that predict their poor response to therapy. Despite even the most aggressive and well-developed strategies for treatment, most patients succumb to the disease. No currently available treatment has demonstrated consistent efficacy in terms of salvage therapy or long-term survival in this group of patients. This review will discuss some of the emerging strategies: targeted molecular therapies, novel cytotoxics, and immune-based therapies to treat relapsed and refractory AML patients.
Keywords
Acute myelogenous leukemia; Relapse; Targeted molecular therapies
About this articleTitle
Acute myeloid leukemia – treatment of relapsed and refractory form
Journal
Issue
Pages
121-127
Published online
2015-04-01
Page views
108
Article views/downloads
188
DOI
10.1016/j.achaem.2015.02.007
Bibliographic record
Acta Haematol Pol 2015;46(2):121-127.
Keywords
Acute myelogenous leukemia
Relapse
Targeted molecular therapies
Authors
Beata Piątkowska-Jakubas
Agnieszka Sporek-Kunicka